See what questions
a doctor would ask.
Article title: Unraveling Autism: NIMH
The National Institute of Mental Health—in collaboration with the National Institute of Child Health and Human Development, the National Institute of Neurological Disorders and Stroke, and the National Institute of Deafness and other Communication Disorders—is searching for answers about the causes, diagnosis, prevention, and treatment of this devastating disorder. Research findings have made it possible to identify earlier those children who show signs of developing autism and thus to initiate early intervention, which can lead to improved cognitive and behavioral outcomes. 4,5
Improved early diagnosis and differentiation of various forms of autism is a goal of brain imaging studies that are building a database on normal brain development in children. Scans of the normal structural and functional maturation of the brain will be compared with those from individuals with autism, speeding development of targeted treatments and evaluations of their effects. Yet even the most advanced scanners cannot substitute for post-mortem brain tissue. Brain banks are working with families to arrange for tissue donation following the deaths of individuals with autism.
While it is known that heredity plays a major role in complex disorders like autism, the identification of specific genes that confer vulnerability to such disorders has proven extremely difficult. 6 Once autism-linked genes are identified, however, scientists will bring to bear sophisticated research tools to find out what activates them, what brain components they code for, and how they affect behavior. The prospect of acquiring such molecular knowledge holds great hope for the engineering of new therapies.
Evidence suggests that unaffected family members may share with their ill relatives genes that predispose for milder behavioral characteristics that are qualitatively similar to those of autism. 7 For example, some relatives of people with autism may have mild social, language, or reading problems. Family members also may share telltale neurochemical signatures that may be implicated in the disorder. 8 Researchers are studying such families to characterize these behavioral and biological traits, in hopes of tracing the variations in the genetic blueprint that contribute to autism.
The behavioral and cognitive functioning of individuals with autism can improve with the help of psychosocial and pharmacological interventions. 4 Among psychosocial treatments, intensive, sustained special education programs and behavior therapy early in life can increase the ability of children with autism to acquire language and the ability to learn. 4,5 NIMH-funded research teams are evaluating the effectiveness of parent-training interventions that are tailored to the particular characteristics of the child and family.
In adults with autism, some studies have found beneficial effects of the antidepressant medications clomipramine and fluoxetine. 9,10 There is also evidence that the antipsychotic medication haloperidol can be helpful; however, the risk of serious side effects is significant in children. 11
The increasing use of psychotropic medications to treat autism in children has spotlighted an urgent need for more studies of such drugs in youths. A network of five NIMH-supported research centers that combine expertise in psychopharmacology and psychiatry are evaluating the atypical antipsychotic risperidone for reducing aggressive self-injurious behavior in children with autism. Other NIMH research is investigating valproate for diminishing this behavior in adolescents with autism. Studies are examining dose range and regimen of medications, and their mechanisms of action, safety, efficacy, and effects on cognition, behavior, and development.
All material in this fact sheet is in the public domain and may be copied or reproduced without permission from the Institute. Citation of the source is appreciated.
NIH Publication No. 01-4590
3 Volkmar F, Cook EH Jr, Pomeroy J, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. Journal of the American Academy of Child and Adolescent Psychiatry, 1999; 38(12 Suppl): 32S-54S.
5 McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal of Mental Retardation, 1993; 97(4): 359-72; discussion 373-91.
10 Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 1993; 50(6): 441-7.
11 Campbell M, Armenteros JL, Malone RP, et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 1997; 36(6): 835-43.
Updated: January 01, 2001
For information about NIMH and its programs, please email, write or phone us.
NIMH Public Inquiries
6001 Executive Boulevard, Rm. 8184, MSC 9663
Bethesda, MD 20892-9663 U.S.A.
Voice (301) 443-4513; Fax (301) 443-4279
TTY (301) 443-8431
Search Specialists by State and City